Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(04): 516-519
DOI: 10.4103/0971-5851.220133
2017 ASCO Highlights on Gastointestinal Malignancies

2017 ASCO Highlights on Gastointestinal Malignancies

Ravi Paluri
Division of Hematology Oncology, Department of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham,
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used forcommercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Park SB et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians 2013; 63(6): 419-437. doi: 10.3322/caac.21204
  • 2 André T et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. Journal of Clinical Oncology 2009; 27(19): 3109-3116. doi: 10.1200/jco.2008.20.6771
  • 3 Shi Q, et al. J Clin Oncol 2017;35(Suppl:Abstr LBA1), Plenary
  • 4 Sobrero AF, et al. J Clin Oncol 2017;35(Suppl:Abstr 3501)
  • 5 Iveson T, et al. J Clin Oncol 2017;35(Suppl:Abstr 3502)
  • 6 André T, et al. J Clin Oncol 2017;35(Suppl:Abstr 3500)
  • 7 Kopetz S, et al. J Clin Oncol 2017;35(Suppl:Abstr 3505)
  • 8 Taieb J et al J Clin Oncol 35, 2017 (suppl; abstr 3515)
  • 9 Sharma RA, et al. J Clin Oncol 2017;35(Suppl:Abstr 3507)
  • 10 Ng K, et al. J Clin Oncol 2017;35(Suppl:Abstr 3506)
  • 11 Al-Batran S-E, et al. J Clin Oncol 2017;35(Suppl:Abstr 4004)
  • 12 Janjigian YY, et al. J Clin Oncol 2017;35(Suppl:Abstr 4014)
  • 13 Fuchs CS, et al. J Clin Oncol 2017;35(Suppl:Abstr 4003)
  • 14 Bang YJ et al J Clin Oncol 2017;35(Suppl:Abstr 4012)
  • 15 Khan SA et al. Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us? Journal of Hepatology 2012; 56(4): 848-854. doi: 10.1016/j.jhep.2011.11.015
  • 16 Primrose JN, et al. J Clin Oncol 2017;35(Suppl:Abstr 4006)
  • 17 Hingorani SR, et al. J Clin Oncol 2017;35(Suppl:Abstr 4008)
  • 18 Safran H, et al. J Clin Oncol 2017;35(Suppl:Abstr 4007)
  • 19 Rimassa L, et al. J Clin Oncol 2017;35(Suppl:Abstr 4000)
  • 20 Cheng A-L, et al. J Clin Oncol 2017;35(Suppl:Abstr 4001)
  • 21 Chow P, et al. J Clin Oncol 2017;35(Suppl:Abstr 4002)
  • 22 Crocenzi TS et al J Clin Oncol 35, 2017 (suppl; abstr 4013)